| Summary: | Submitted by Caroline Xavier (caroline.xavier@pucrs.br) on 2017-08-25T18:56:36Z
No. of bitstreams: 1
TES_DANIEL_DOLIVEIRA_SILVA_CONFIDENCIAL.pdf: 262553 bytes, checksum: 4a53c6ec3ea6da2ddc6cd64d93f5925c (MD5) === Approved for entry into archive by Caroline Xavier (caroline.xavier@pucrs.br) on 2017-08-25T18:56:47Z (GMT) No. of bitstreams: 1
TES_DANIEL_DOLIVEIRA_SILVA_CONFIDENCIAL.pdf: 262553 bytes, checksum: 4a53c6ec3ea6da2ddc6cd64d93f5925c (MD5) === Made available in DSpace on 2017-08-25T18:56:55Z (GMT). No. of bitstreams: 1
TES_DANIEL_DOLIVEIRA_SILVA_CONFIDENCIAL.pdf: 262553 bytes, checksum: 4a53c6ec3ea6da2ddc6cd64d93f5925c (MD5)
Previous issue date: 2017-05-19 === Purpose: to determine the usefulness of serum TF as a potential marker for patients with clear cell RCC.
Materials and Methods: prospective study of 30 patients with clear cell RCC submitted to nephrectomy and 16 controls without clear cell RCC treated surgically for other conditions. TF is a endothelium marker that was correlated with worse prognosis in a variety of solid tumors including RCC. Serum TF was collected before surgery at the operating room and in the postoperative setting after at least four weeks. Serum samples were analyzed with a commercial ELISA kit for human TF (R&D Systems ?).
Results: Mean preoperative serum TF levels in clear cell RCC patients and in controls were 66.8 pg/dl and 28.4 pg/dl, respectively (p<0.001). Mean postoperative serum TF levels in clear cell RCC patients were 26.3 pg/dl. In all patients with clear cell RCC postoperative serum levels of TF were lower, with a mean reduction of 41.6 pg/dl in the postoperative setting (p<0.001). Linear regression revealed that tumor size was correlated with the postoperative reduction of serum TF levels (p=0.037).
Conclusions: We have shown a 3-fold reduction in the median preoperative serum levels of TF in patients with clear cell RCC after surgery. We have also shown a difference of the same magnitude in the serum levels of TF compared with those of a control group of patients with benign diseases. TF appears to be a useful serum marker for the presence of clear cell RCC. Further studies are needed to validate these findings. === O c?ncer renal ? uma das neoplasias malignas mais letais. As taxas de mortalidade t?m crescido mundialmente a despeito da evolu??o do diagn?stico precoce e do surgimento de novos f?rmacos ativos na terapia da doen?a sist?mica. Atualmente, para se estabelecer riscos de morbimortalidade em c?ncer renal os pacientes s?o classificados de acordo com escalas e nomogramas, que ainda n?o conseguem predizer com grande acur?cia a evolu??o cl?nica dos mesmos. Nosso estudo foi realizado com o objetivo de determinar a utilidade da dosagem do Fator Tecidual (FT) no soro como potencial marcador para pacientes comCarcinoma de C?lulas Claras de Rim (CCCr).Realizamos um estudo prospectivo com 30 pacientes com CCCr submetidos ? nefrectomia e 16 controles sem CCCr tratados cirurgicamente para outras condi??es. O FT s?rico foi coletado na sala cir?rgica antes do procedimento e no p?s-operat?rio ap?s pelo menos quatro semanas. Os n?veis s?ricos detectados no pr?-operat?rio foram tr?s vezes mais altos em pacientes com CCCr do que nos controles, e dininu?ram em todos os pacientes com CCCr no p?s-operat?rio, com uma redu??o m?dia de 41,6 pg/ml (p <0,001). Nossos achados sugerem que oFTpode ser utilizado como um marcador s?rico para a presen?a de CCCr.
|
|---|
